Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: An analysis from the GMALL study group

Haematologica

Volumn 99, Issue 2, 2014, Pages

  Burmeister, Thomas ^a   Bartels, Gesine ^a   Gröger, Daniela ^a   Trautmann, Heiko ^b   Schwartz, Stefan ^a   Lenz, Klaus ^c   Tietze Bürger, Carola ^d   Viardot, Andreas ^e   Wäsch, Ralph ^f   Horst, Heinz August ^b   Reinhardt, Richard ^g   Gökbuget, Nicola ^h   Hoelzer, Dieter ^h   Kneba, Michael ^b   Brüggemann, Monika ^b  

^a Klinik für Hämatologie Onkologie und Tumorimmunologie   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Department of Psychiatry   (Germany)

^d Klinik für Innere Medizin III ^*

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g Max Planck Genomzentrum   (Germany)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukemia; Adult onset; ARID5B; CEBPE; Germline variants; IKFZ1; Risk factors

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARID5B GENE; CDKN2A GENE; CEBPE GENE; FLOW CYTOMETRY; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; IKZF1 GENE; IMMUNOPHENOTYPING; LETTER; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT-ONSET; ARID5B; CEBPE; GERMLINE VARIANTS; IKFZ1; RISK FACTORS;

ADOLESCENT; ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEINS; DNA-BINDING PROTEINS; FEMALE; GERM-LINE MUTATION; HUMANS; IKAROS TRANSCRIPTION FACTOR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 84896738249     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.090720     Document Type: Letter

References (14)

1. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1006-10.
2. Treviño LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1001-5.
3. Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010;42(6):492-4.
4. Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M, et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood. 2010;115(9):1765-7.
5. Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, et al. The MLL recombinome of adult CD10-negative Bcell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood. 2009;113(17):4011-5.
6. Burmeister T, Gökbuget N, Schwartz S, Fischer L, Hubert D, Sindram A, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica. 2010;95(2):241-6.
7. Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116-23.
8. Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20(3):451-7.
9. Gast A, Bermejo JL, Flohr T, Stanulla M, Burwinkel B, Schrappe M, et al. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia. 2007;21(2):320-5.
10. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-78.
11. van Vlierberghe P, Palomero T, Khiabanian H, van der Meulen J, Castillo M, van Roy N, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(4):338-42.
12. Peyrouze P, Guihard S, Grardel N, Berthon C, Pottier N, Pigneux A, et al. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.[letter]. Br J Haematol 2012;159(5):599-613.
13. Sherborne AL, Hemminki K, Kumar R, Bartram CR, Stanulla M, Schrappe M, et al. Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. Haematologica. 2011;96(7):1049-54.
14. Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012;30(7):751-7.